Form 8-K - Current report:
SEC Accession No. 0001193125-25-141748
Filing Date
2025-06-17
Accepted
2025-06-17 07:18:43
Documents
18
Period of Report
2025-06-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d30505d8k.htm   iXBRL 8-K 64250
2 EX-2.1 d30505dex21.htm EX-2.1 600876
3 EX-2.2 d30505dex22.htm EX-2.2 78041
4 EX-2.3 d30505dex23.htm EX-2.3 67812
5 EX-2.4 d30505dex24.htm EX-2.4 67682
6 EX-99.1 d30505dex991.htm EX-99.1 22725
10 GRAPHIC g30505dsp74a.jpg GRAPHIC 7265
  Complete submission text file 0001193125-25-141748.txt   1262653

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA verv-20250616.xsd EX-101.SCH 2850
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20250616_lab.xml EX-101.LAB 17994
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20250616_pre.xml EX-101.PRE 11261
20 EXTRACTED XBRL INSTANCE DOCUMENT d30505d8k_htm.xml XML 3638
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 251051818
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)